home / stock / acrs / acrs quote
Last: | $1.14 |
---|---|
Change Percent: | -2.61% |
Open: | $1.18 |
Close: | $1.14 |
High: | $1.19 |
Low: | $1.12 |
Volume: | 641,145 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.14 | $1.18 | $1.14 | $1.19 | $1.12 | 641,145 | 07-02-2024 |
$1.15 | $1.1 | $1.15 | $1.27 | $1.1 | 1,651,825 | 07-01-2024 |
$1.1 | $1.13 | $1.1 | $1.16 | $1.1 | 9,375,810 | 06-28-2024 |
$1.11 | $1.12 | $1.11 | $1.18 | $1.1 | 894,143 | 06-27-2024 |
$1.115 | $1.28 | $1.115 | $1.28 | $1.11 | 830,925 | 06-26-2024 |
$1.29 | $1.28 | $1.29 | $1.29 | $1.24 | 731,974 | 06-25-2024 |
$1.29 | $1.15 | $1.29 | $1.29 | $1.14 | 982,811 | 06-24-2024 |
$1.15 | $1.14 | $1.15 | $1.15 | $1.11 | 470,269 | 06-21-2024 |
$1.13 | $1.16 | $1.13 | $1.165 | $1.1 | 493,680 | 06-20-2024 |
$1.13 | $1.12 | $1.13 | $1.18 | $1.115 | 564,672 | 06-19-2024 |
$1.13 | $1.12 | $1.13 | $1.18 | $1.115 | 564,672 | 06-18-2024 |
$1.13 | $1.2 | $1.13 | $1.2 | $1.095 | 905,219 | 06-17-2024 |
$1.18 | $1.22 | $1.18 | $1.2297 | $1.15 | 1,003,921 | 06-14-2024 |
$1.19 | $1.14 | $1.19 | $1.22 | $1.11 | 974,061 | 06-13-2024 |
$1.15 | $1.11 | $1.15 | $1.175 | $1.09 | 521,107 | 06-12-2024 |
$1.12 | $1.06 | $1.12 | $1.135 | $1.01 | 1,444,076 | 06-11-2024 |
$1.06 | $0.991 | $1.06 | $1.07 | $0.99031 | 298,447 | 06-10-2024 |
$1.01 | $1.02 | $1.01 | $1.03 | $1 | 307,332 | 06-07-2024 |
$1.03 | $1.05 | $1.03 | $1.06 | $1.01 | 269,503 | 06-06-2024 |
$1.05 | $1.04 | $1.05 | $1.05 | $1.01 | 241,846 | 06-05-2024 |
News, Short Squeeze, Breakout and More Instantly...
Aclaris Therapeutics Inc. Company Name:
ACRS Stock Symbol:
NASDAQ Market:
Aclaris Therapeutics Inc. Website:
WAYNE, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, Interim President & CEO of Aclaris, will part...
- Progressing ATI-2138 into Atopic Dermatitis - - Management to Host Conference Call at 5:00 PM ET Today - WAYNE, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidat...
Aterian Inc. (ATER) is expected to report for Q1 2024 Dorman Products Inc. (DORM) is expected to report $0.82 for Q1 2024 Hillman Solutions Corp. (HLMN) is expected to report $0.08 for Q1 2024 Wake Forest Bancshares, Inc. (WAKE) is expected to report for quarter end 2024-03-31 Inn...